Skip to main content
CING
NASDAQ Life Sciences

FDA Issues Complete Response Letter for Lead ADHD Drug CTx-1301

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.79
Mkt Cap
$47.794M
52W Low
$3.16
52W High
$11.89
52W Position info
20% above low
Off High info
68% below high
Rel. Volume info
3.7× avg
Market data snapshot near publication time

CING sits 20% above its 52-week low of $3.16 on elevated volume (3.7× avg).

Summary

Cingulate Inc. received a Complete Response Letter from the FDA for its lead ADHD drug, CTx-1301, citing manufacturing and controls issues, which delays the drug's approval and commercialization.


Key Events · Product Development and Regulatory · CING

  • FDA Issues CRL for CTx-1301

    The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for the New Drug Application (NDA) of CTx-1301, Cingulate's lead ADHD drug candidate.

  • CMC Issues Cited

    The CRL primarily focused on Chemistry, Manufacturing, and Controls (CMC) information requests, with no current concerns raised regarding clinical safety or efficacy.

  • Approval Delayed

    This decision delays the potential approval and commercialization of CTx-1301, requiring a resubmission of requested information to the FDA.

  • Cash Runway

    Cingulate stated it has nearly $30 million in cash reserves, which it believes is sufficient to address the issues and continue pre-commercial activities into early 2027.


Analysis · CING · Life Sciences

The FDA's Complete Response Letter (CRL) for Cingulate's lead ADHD drug candidate, CTx-1301, is a significant setback, delaying potential market entry and revenue generation. While the CRL primarily cites Chemistry, Manufacturing, and Controls (CMC) issues rather than clinical safety or efficacy, it still requires a resubmission and further review, extending the timeline for approval. This event is critical for a company that previously disclosed a "going concern" warning and relies heavily on this product for its future. The company's stated cash reserves of nearly $30 million are crucial to fund the resubmission process and ongoing operations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CING was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.8M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CING - Latest Insights

CING
Nov 13, 2026, 5:22 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $4.61 info
Change: +$0.360 (+8%) info
Market Cap: $67.483M info
CING
Nov 13, 2026, 5:19 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $4.61 info
Change: +$0.360 (+8%) info
Market Cap: $67.483M info
CING
Nov 10, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $4.61 info
Change: -$0.140 (-3%) info
Market Cap: $67.483M info
CING
Aug 13, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.12
Real-time Price: $4.61 info
Change: -$0.510 (-10%) info
Market Cap: $67.483M info
CING
Aug 13, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.12
Real-time Price: $4.61 info
Change: -$0.510 (-10%) info
Market Cap: $67.483M info